The Right Treatment for the Right Patient at the Right Time
Following the development of the first all-inclusive genomics test approved by the New York State Department of Health, the Englander Institute for Precision Medicine has made genetic sequencing widely available for cancer patients at NewYork-Presbyterian Hospital/Weill Cornell Medicine. Using a precision medicine approach that considers individual variability in genes, environment, and lifestyle for each person, our clinicians continue to accurately prescribe targeted therapies to treat specific diseases.
The Englander Institute offers tumor sequencing to patients with advanced or refractory cancer or those cancer types that lack available effective therapy. Our efforts help clinicians and researchers understand tumor biology and drug resistance, and allow for the testing of novel therapeutics and targeted therapies.
1. Must have a confirmed or suspected diagnosis of cancer (any type)
2. Tumor tissue is available by at least one of the following methods:
a. Archival frozen or formalin fixed paraffin embedded (FFPE) tissue,
b. Patient is undergoing standard of care surgery or procedure where specimens will be first used for routine pathologic assessment and only then will leftover (otherwise waste/discarded) tissue be used for research purposes.
3. Tumor evaluation through plasma (circulating tumor DNA) extracted from blood.
4. Clinical genetic sequencing has been or will be ordered.
NOTE: This is not a therapeutic trial.
Patients are seen on a referral only basis. If you are a patient interested in precision medicine, please speak with your clinician or contact or submit inquiries and contact information to email@example.com
- NewYork-Presbyterian/Weill Cornell Medicine patients contact your clinician in the Department of Hematology and Medical Oncology to learn more
- NewYork-Presbyterian/Weill Cornell Medicine clinicians contact firstname.lastname@example.org for referrals
- External patients and clinicians may submit inquiries and contact information to email@example.com
Care Beyond Cancer
With multiple clinical diagnosis and treatments benefitting from translational research, the Englander Institute has expanded investigations beyond cancer. We are exploring new disease areas where genomics and a multi-faceted approach may influence treatment and prevention. Stay tuned for more information!